Subscribe To
Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities
Strong demand for financing including full exercise of overallotment option with net proceeds of $63.3 million Cash runway extended into Q1 2025 Phase 2 Photoparoxsymal Response (PPR) study to evaluate PRAX-628 expected to read-out by YE 2023 Plan to begin ulixacaltamide Phase 3 enrollment in Q4 2023 to support a 2025 NDA filing BOSTON, June […] The post Praxis Precision Medicines Announces Closing of Financing and Reiterates Corporate Priorities appeared first on ForexTV...
Read More
Content Topics
Praxis
Precision
Medicines
Announces
Closing
Financing
Reiterates
Corporate
Priorities
Forex
Posted: Jun 22 2023, 11:00
Author Name: forextv
Views: 081117